温肾健脾法对腹泻型肠易激综合征动物模型内脏敏化NMDAR作用的研究

Irritable bowel syndrome (IBS) is a functional disease of recurrent clinical manifestations of abdominal pain, bloating and bowel habits and stool changes. Our previous studies have shown that treatment of spleen Warming-IBS mainly by regulating colonic mucosa, ileocecal nerve - endocrine - immune network play a therapeutic role. Literature studies have shown that IBS recurrent visceral sensitization, whereas NMDAR channels and central sensitization, visceral pain, and is closely related to the generation and maintenance of hyperalgesia. Therefore, the hypothesis put forward: Warming spleen law changes by adjusting the NMDA receptor activity and content, to inhibit diarrhea-predominant IBS visceral sensitization effect. And through the study of diarrhea-predominant irritable bowel syndrome rat model behavior, organizational NMDA receptor expression levels, visceral sensitization to explore the biological characteristics; and by studying law Warming spleen intervention diarrhea-predominant IBS, abdominal pain model further research regulation Warming spleen method on visceral sensitization; visceral sensitization aims to clarify the perspective of Chinese medicine and therapeutic targets for prevention and treatment of IBS, and provide a new theoretical basis for the prevention and Treatment of IBS.

肠易激综合征（IBS）是一种反复发作的功能性疾病，临床表现为腹痛、腹胀及排便习惯和大便性状的改变。本课题组前期研究表明，温肾健脾法治疗腹泻型IBS主要是通过调节结肠黏膜、回盲部神经-内分泌-免疫网络发挥治疗作用。文献研究表明IBS反复发作性与内脏敏化有关，而NMDAR通道与中枢敏化、内脏疼痛以及痛觉过敏的产生和维持密切相关。因此，提出假说：温肾健脾法能通过调节NMDA受体活性和含量的变化，达到抑制腹泻型IBS内脏敏化的作用。并通过研究腹泻型肠易激综合征模型大鼠行为学、组织中NMDA受体表达水平，探讨内脏敏化的生物学特点；并通过研究温肾健脾法对腹泻型IBS腹痛模型的干预，进一步研究温肾健脾法对内脏敏化的调节作用;旨在从内脏敏感化角度阐明中医药防治IBS的作用靶点和疗效机制，为防治IBS的研究提供新的理论依据。